about
Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251Association between a cell-seeded collagen matrix and cellular cardiomyoplasty for myocardial support and regenerationPUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells.Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta.Accelerated tumor development in interferon-treated B6.C-Hyal-1 a mice.CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress.The Notch ligand delta-1 is a hematopoietic development cofactor for plasmacytoid dendritic cells.Notch/Delta4 interaction in human embryonic liver CD34+ CD38- cells: positive influence on BFU-E production and LTC-IC potential maintenance.Stable antiviral expression (SAVE) as an approach to somatic cell gene therapy directed against HIV infection.Autocrine interferon-beta synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals.Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.Macaque lymphocytes transduced by a constitutively expressed interferon beta gene display an enhanced resistance to SIVmac251 infection.Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. II. Unresponsiveness of isolated adult rat hepatocytes, 3T3, FDC-P2, and K562 cell lines to AcSDKP. Possible involvement of intermediary cell(s) in the mechaniNotch/Delta4 signaling inhibits human megakaryocytic terminal differentiation.HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma.Expression of human and macaque type I IFN transgenes interferes with HSV-1 replication at the transcriptional and translational levels: IFN-beta is more potent than IFN-alpha 2.Simian immunodeficiency virus resistance of macaques infused with interferon beta-engineered lymphocytes.Inhibition of HIV replication: a powerful antiviral strategy by IFN-beta gene delivery in CD4+ cells.Transgenic Mice Expressing Human Proteinase 3 Exhibit Sustained Neutrophil-Associated Peritonitis.Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway.Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.The Notch Delta-4 ligand helps to maintain the quiescence and the short-term reconstitutive potential of haematopoietic progenitor cells through activation of a key gene network.Développement d'une génothérapie anti-VIH basée sur les propriétés antivirales de l'interféron bêtaFurther studies on the mechanism of CFU-S determination--II. Feedback regulationAbrogation of the biological activity of the CFU-S inhibitor AcSDKP by a polyclonal antiserumEffects of various treatments of CFU-S seeding efficiency in miceTelomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutantDistinct effects of the soluble versus membrane-bound forms of the notch ligand delta-4 on human CD34+CD38low cell expansion and differentiation
P50
Q24802826-1FA8BFBE-9275-4C4D-98EC-BC3625C15D55Q28240250-48D3AC2B-AA58-44F6-9244-96C43ED4C191Q33675855-8CD55E8F-42C1-4E8B-B165-11B2BB921D35Q35129626-878CC75C-7E47-45E4-8F80-D25DD9917C71Q36371647-47361AAF-DE4B-47D8-8A03-AEF41BA2CD01Q39154440-708E12D3-EBD8-4FC0-A417-66338A11736EQ40339560-1203AA58-5473-4079-B62D-9A8EEA911A70Q40442591-3D7D615F-9DC5-46BD-92C9-2FAC1676FC09Q40500318-D7E0838F-2B03-44A2-B7F9-E47FB90C6D91Q41276411-4109340A-2E02-4FA5-A832-0FF97A1A20C3Q42520569-87773EAB-336C-4C46-A0FA-9296B060F4FBQ42818971-EF9AF408-DD38-489C-BE07-9659E626D4C1Q42834620-40E3F060-2897-435E-BEE2-F0B8461C1D95Q42911718-A3674622-21D7-4807-B96D-631639FEDBE2Q43828372-995C7105-DE4C-427A-A71B-A8094B57212EQ43908614-206468F2-FC45-4E02-9851-3C9E2FBB8F16Q45740149-B02DEC85-0445-4F8B-965A-D53E06DF609EQ45869827-FB0931CD-08D0-4B69-944B-4EB40F806478Q47592618-049C1131-AAA7-46C6-B5AC-D3592B39785FQ47966993-F58B9E6D-214E-4232-B989-CC6D948A82C2Q51322008-59DD42BD-2B34-4622-8721-237916D700DDQ52997644-EC0E48C2-99FD-44F2-908F-3F4EA956C155Q61457467-40AD841C-09BE-4EC9-BBFB-B8849ACDA286Q68969568-A5C34BAF-B697-4386-AE90-62CF46BAEFF2Q69967714-4B0EED2D-FE9F-48F4-9A6B-D0B8B338E281Q72590650-EC6F098B-B5A8-404E-B607-E4977C93133CQ78560248-AF76720F-8FD9-45BE-BB76-1F199744BA5FQ80137241-D835AC4B-A004-4DE5-969E-716FE3F97773
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Evelyne Lauret
@ast
Evelyne Lauret
@en
Evelyne Lauret
@es
Evelyne Lauret
@nl
type
label
Evelyne Lauret
@ast
Evelyne Lauret
@en
Evelyne Lauret
@es
Evelyne Lauret
@nl
prefLabel
Evelyne Lauret
@ast
Evelyne Lauret
@en
Evelyne Lauret
@es
Evelyne Lauret
@nl
P106
P31
P496
0000-0003-4643-6857